Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE The purpose of this study was to characterize the transcriptional effects induced by intramuscular IFN-β-1a therapy in patients with relapsing-remitting form of MS. By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells of 24 MS patients within the first 4 weeks of IFN-β administration. 20956993

2012

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Thyroid dysfunction and autoimmunity have been reported during type I interferon therapy, namely interferon-alpha for chronic hepatitis or interferon-beta for multiple sclerosis. 11502774

2001

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Despite substantial progress made in the field, there is still a long way to go before biomarker discoveries can be incorporated into clinical practice to predict IFN-β-responder status in MS patients. 20836710

2010

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 GeneticVariation BEFREE The aim of this study was to evaluate the prognostic value of select clinical scores in interferon beta-1b (IFNβ-1b) treated MS patients. 31793659

2019

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 GeneticVariation BEFREE An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. 16430971

2006

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Interferonbeta-1b (IFNβ-1b) developed as therapeutic protein for the treatment of multiple sclerosis (MS). 31522451

2019

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. 21680782

2012

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up. 30401571

2019

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Serum samples from 104 patients with multiple sclerosis (MS) treated with IFNbeta were tested for NAbs using our real time PCR bioassay. 17335844

2007

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Multiple sclerosis (MS), an autoimmune inflammatory/neurodegenerative disease of the CNS, requires long-term medication with either specific disease-modifying therapy (DMT) - IFN-β or glatiramer acetate (GA) - which remain the only first-line DMTs in all countries. 24798724

2014

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Interferon-beta is used to reduce disease activity in multiple sclerosis, but its action is incompletely understood, individual treatment response varies among patients, and biological markers predicting clinical benefits have yet to be identified. 22086901

2012

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE We aimed at investigating whether switching to intramuscular IFNB-1a injected once/week with the Avonex®Pen™ device improves treatment tolerability and quality of life in stable MS patients. 30763907

2019

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE The NAbs against IFN-β were measured in BAb-positive MS patients receiving IFN-β using an MxA gene expression assay (real-time RT-PCR). 24339712

2013

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. 20610349

2010

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Interferon-beta (IFN-beta) is the principle immune-modulatory agent used in the treatment of MS, but its mechanism of action remains elusive. 15652415

2005

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Therapeutic CTD_human Seizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and clomipramine. 12432978

2002

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 GeneticVariation BEFREE The aim of this cohort analysis was to estimate real-world discontinuation rates up to 3 years among MS patients in the United States taking subcutaneous (sc) IFN β-1a three times a week (tiw) and to identify whether the factors associated with discontinuation change over time. 28335743

2017

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE We will primarily focus our research considerations on the role of Interferon Beta (IFN-beta) as a prototypal therapeutic agent in Multiple Sclerosis. 16311019

2005

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 AlteredExpression BEFREE Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. 16867161

2006

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 GeneticVariation BEFREE The aim of the present study is to analyse the effects of MLT administration in comparison with the first-line treatments for MS (IFN-β and GA). 29526318

2018

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.Mult Scler.Epub ahead of print 31 August 2017. 28956510

2017

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Recombinant human interferon beta (rIFN-β) has long been used as a first-line treatment for multiple sclerosis (MS), and any attempt to develop a long-acting rIFN-β is desirable since only one pegylated version of long-acting rIFN-β-1a (Plegridy) is currently available in clinics. 30684504

2019

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. 21061396

2010

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 Biomarker BEFREE A young Caucasian female with multiple sclerosis on chronic therapy with interferon-β presented with acute rhabdomyolysis after mild exercise and concomitant ingestion of pomelo extract. 28655386

2018

Entrez Id: 3456
Gene Symbol: IFNB1
IFNB1
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis
0.400 AlteredExpression BEFREE We showed previously, in a cell model of spinocerebellar ataxia 7, that interferon beta induces the expression of PML protein and the formation of PML protein nuclear bodies that degrade mutant ataxin 7, suggesting that the cytokine, used to treat multiple sclerosis, might have therapeutic value in spinocerebellar ataxia 7. 23518714

2013